New ‘Emergency’ Market Beckons For Spravato Depression Spray
The therapeutic indication of Spravato is set to be expanded in the EU after receiving the thumbs up from the European Medicines Agency. The nasal spray has been shown to reduce depressive symptoms in just four hours and would fill a key unmet need, says the drug’s developer, Janssen.
You may also be interested in...
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
The European Medicines Agency has recommended that the therapeutic indications of Keytruda and Bavencio should be expanded again.